The market opportunity for the drug is huge in the world’s most populous country, where obesity rates are high especially among women. Illegal copycat versions of Wegovy are already being sold through online sites.
https://www.pharmalive.com/wp-content/uploads/2023/09/Novo-Nordisk-logo.jpg500656Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-09-29 05:18:532023-09-29 10:03:14Novo Nordisk India head eyes 2026 Wegovy launch, warns against copycats